Io Biotech Stock Performance
| IOBT Stock | USD 0.88 0.01 1.12% |
On a scale of 0 to 100, IO Biotech holds a performance score of 6. The company owns a Beta (Systematic Risk) of 0.34, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, IO Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding IO Biotech is expected to be smaller as well. Please check IO Biotech's standard deviation, expected short fall, period momentum indicator, as well as the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether IO Biotech's current price history will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in IO Biotech are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak fundamental drivers, IO Biotech unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | IO Biotech secures up to 57.5 million in debt financing from the European Investment Bank | 12/20/2024 |
2 | IO Biotech, Inc. Short Interest Up 210.5 percent in December - MarketBeat | 12/26/2024 |
3 | Insider Trading | 01/10/2025 |
4 | IO Biotech, Inc. Sees Large Decrease in Short Interest - MarketBeat | 01/13/2025 |
5 | Acquisition by Hunter Heidi of 64238 shares of IO Biotech at 1.83 subject to Rule 16b-3 | 01/21/2025 |
6 | IO Biotech, Inc. Short Interest Update - MarketBeat | 01/28/2025 |
7 | IO Biotech to Present at the 45th Annual Cowen Health Care Conference | 02/20/2025 |
8 | Acquisition by Elling Christian E of 23885 shares of IO Biotech subject to Rule 16b-3 | 03/04/2025 |
9 | Acquisition by Hbm Healthcare Investments Ltd. of 325000 shares of IO Biotech at 14.0 subject to Rule 16b-3 | 03/06/2025 |
10 | Acquisition by Novo Holdings As of 2469135 shares of IO Biotech at 2.025 subject to Rule 16b-3 | 03/12/2025 |
11 | IO Biotech Upgraded to Strong-Buy at Piper Sandler | 03/14/2025 |
| Begin Period Cash Flow | 142.9 M |
IOBT |
IO Biotech Relative Risk vs. Return Landscape
If you would invest 76.00 in IO Biotech on December 17, 2024 and sell it today you would earn a total of 12.00 from holding IO Biotech or generate 15.79% return on investment over 90 days. IO Biotech is currently generating 0.3263% in daily expected returns and assumes 4.1183% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than IOBT, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
IO Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for IO Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as IO Biotech, and traders can use it to determine the average amount a IO Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0792
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IOBT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.12 actual daily | 36 64% of assets are more volatile |
Expected Return
| 0.33 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average IO Biotech is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of IO Biotech by adding it to a well-diversified portfolio.
IO Biotech Fundamentals Growth
IOBT Stock prices reflect investors' perceptions of the future prospects and financial health of IO Biotech, and IO Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IOBT Stock performance.
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | (20.7 M) | ||||
| Shares Outstanding | 65.88 M | ||||
| Price To Book | 0.79 X | ||||
| EBITDA | (91.23 M) | ||||
| Net Income | (86.08 M) | ||||
| Cash And Equivalents | 170.12 M | ||||
| Cash Per Share | 5.90 X | ||||
| Total Debt | 2.49 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 20.94 X | ||||
| Book Value Per Share | 1.10 X | ||||
| Cash Flow From Operations | (71.74 M) | ||||
| Earnings Per Share | (1.29) X | ||||
| Market Capitalization | 57.9 M | ||||
| Total Asset | 150.72 M | ||||
| Retained Earnings | (263.82 M) | ||||
| Working Capital | 131.54 M | ||||
About IO Biotech Performance
Assessing IO Biotech's fundamental ratios provides investors with valuable insights into IO Biotech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the IO Biotech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (932.57) | (979.20) | |
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.78) | (0.74) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.74) | (0.71) |
Things to note about IO Biotech performance evaluation
Checking the ongoing alerts about IO Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for IO Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| IO Biotech has some characteristics of a very speculative penny stock | |
| IO Biotech had very high historical volatility over the last 90 days | |
| Net Loss for the year was (86.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| IO Biotech currently holds about 170.12 M in cash with (71.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| IO Biotech has a frail financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: IO Biotech Upgraded to Strong-Buy at Piper Sandler |
- Analyzing IO Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether IO Biotech's stock is overvalued or undervalued compared to its peers.
- Examining IO Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating IO Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of IO Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of IO Biotech's stock. These opinions can provide insight into IO Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.